For years, the public has heard a consistent message: to protect against cervical cancer, you need two or three doses of the HPV vaccine. But new research published in the Canadian Medical Association Journal turns that belief on its head. The study makes a compelling case that a single dose of the Gardasil-9 vaccine offers protection on par with two or three doses at least for people ages nine to twenty.
This isn’t just an academic finding; it’s a public health game-changer. If one shot works as well as multiple doses, why are we still asking families to schedule repeat visits, and why are we spending extra money and staff time to deliver doses that might not even be necessary?
The evidence is strong. Dr. Chantal Sauvageau, a public health physician and co-author of the study, notes that a one-dose schedule prevents just as many HPV infections and cancers as the traditional regimen provided the protection holds through the years when people are most sexually active. The National Advisory Committee on Immunization (NACI) agrees. In July, it updated its guidelines to recommend just one dose for Canadians ages nine to twenty. Adults over twenty now need only two doses, not three, unless they are immunocompromised or living with HIV.
This shift is not reckless; it’s responsible. It mirrors the World Health Organization’s own guidance and aligns Canada with countries like the U.K. and Australia, where similar one-dose schedules are already in place. The benefits go beyond convenience. Fewer appointments mean nurses can spend more time on other critical health needs. Lower costs mean public health budgets stretch further. And an easier schedule is likely to boost vaccine uptake an especially big win when HPV is one of the most common sexually transmitted infections in the country.
Critics might argue that one dose is still “new science,” and yes, more data will emerge over time. But public health shouldn’t be frozen by caution when the evidence is already robust and global authorities are on board. HPV causes nearly all cases of cervical cancer. In Canada alone, over 1,700 women were diagnosed with cervical cancer in 2022, and more than 700 died from it. A simpler, equally effective vaccine program could help drive those numbers down even faster.
One dose protects, saves money, frees up resources, and could help eliminate cervical cancer altogether. It’s time we stop clinging to outdated protocols and embrace the science. The HPV vaccine is one of the best tools we have let’s make it as easy as possible for everyone to use it.
